Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro

Human cytomegalovirus (HCMV) infection and reactivation are a major cause of morbidity in immune-suppressed patients. Interestingly, epidemiological studies have shown that patients administered the mammalian target of rapamycin (mTOR) inhibitor, sirolimus (rapamycin), exhibit more favourable outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Glover, Thomas E., Kew, Verity G., Reeves, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for General Microbiology 2014
Materias:
Animal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165932/
https://www.ncbi.nlm.nih.gov/pubmed/24986086
http://dx.doi.org/10.1099/vir.0.066332-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165932/
https://www.ncbi.nlm.nih.gov/pubmed/24986086
http://dx.doi.org/10.1099/vir.0.066332-0

Ejemplares similares